Capital Advisors Inc. OK Invests $205,000 in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Capital Advisors Inc. OK purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, Holdings Channel reports. The fund purchased 496 shares of the company’s stock, valued at approximately $205,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Chicago Partners Investment Group LLC boosted its position in IDEXX Laboratories by 16.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after buying an additional 96 shares during the period. National Pension Service raised its stake in shares of IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company’s stock valued at $93,957,000 after acquiring an additional 12,647 shares during the last quarter. Insight Wealth Strategies LLC lifted its holdings in shares of IDEXX Laboratories by 230.5% during the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock worth $4,174,000 after purchasing an additional 7,041 shares during the period. Larson Financial Group LLC grew its stake in shares of IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock worth $1,139,000 after purchasing an additional 2,241 shares during the last quarter. Finally, Quest Partners LLC increased its holdings in IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after purchasing an additional 2,801 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Finally, Piper Sandler raised their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,330 shares of company stock valued at $6,161,276. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $457.35 on Thursday. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company has a market cap of $37.45 billion, a PE ratio of 42.86, a P/E/G ratio of 3.47 and a beta of 1.37. The stock has a 50-day moving average of $429.67 and a 200-day moving average of $453.23. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.